Should all S2 and S3 medicines to be kept behind the counter, with a completely separate area for CMs? And who supports this proposition? Recently the Review of Pharmacy Remuneration and Regulation released its interim report, and submissions to the report have begun flowing in over the past few weeks. One contentious suggestion by the
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.